New drug combo aims to control blood cancer in early phase
NCT ID NCT02689440
Summary
This study is testing whether combining two drugs, dasatinib and venetoclax, can better control early-stage chronic myeloid leukemia (CML) than one drug alone. It will involve about 155 adults newly diagnosed with this type of blood cancer. The main goal is to see if the combination leads to a deeper reduction of leukemia cells in the blood within the first year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.